KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Payables (2016 - 2025)

Acadia Pharmaceuticals has reported Payables over the past 16 years, most recently at $10.9 million for Q4 2025.

  • Quarterly results put Payables at $10.9 million for Q4 2025, down 32.66% from a year ago — trailing twelve months through Dec 2025 was $10.9 million (down 32.66% YoY), and the annual figure for FY2025 was $10.9 million, down 32.66%.
  • Payables for Q4 2025 was $10.9 million at Acadia Pharmaceuticals, down from $21.7 million in the prior quarter.
  • Over the last five years, Payables for ACAD hit a ceiling of $21.7 million in Q3 2025 and a floor of $6.9 million in Q4 2021.
  • Median Payables over the past 5 years was $14.5 million (2022), compared with a mean of $14.5 million.
  • Biggest five-year swings in Payables: surged 122.47% in 2021 and later crashed 32.66% in 2025.
  • Acadia Pharmaceuticals' Payables stood at $6.9 million in 2021, then soared by 85.37% to $12.7 million in 2022, then skyrocketed by 37.64% to $17.5 million in 2023, then fell by 7.7% to $16.2 million in 2024, then tumbled by 32.66% to $10.9 million in 2025.
  • The last three reported values for Payables were $10.9 million (Q4 2025), $21.7 million (Q3 2025), and $20.1 million (Q2 2025) per Business Quant data.